BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 37046071)

  • 1. Prostate cancer metastasis and health disparities: a systematic review.
    Liadi Y; Campbell T; Dike P; Harlemon M; Elliott B; Odero-Marah V
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):183-191. PubMed ID: 37046071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
    Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
    JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.
    Dovey ZS; Nair SS; Chakravarty D; Tewari AK
    Cancer Rep (Hoboken); 2021 Oct; 4(5):e1340. PubMed ID: 33599076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.
    Mahal BA; Gerke T; Awasthi S; Soule HR; Simons JW; Miyahira A; Halabi S; George D; Platz EA; Mucci L; Yamoah K
    Eur Urol Oncol; 2022 Feb; 5(1):18-29. PubMed ID: 34446369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
    Kelly SP; Anderson WF; Rosenberg PS; Cook MB
    Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic disparities in prostate cancer between American men of African and European descent.
    Abraham-Miranda J; Awasthi S; Yamoah K
    Crit Rev Oncol Hematol; 2021 Aug; 164():103426. PubMed ID: 34273500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial disparities in Black men with prostate cancer: A literature review.
    Lillard JW; Moses KA; Mahal BA; George DJ
    Cancer; 2022 Nov; 128(21):3787-3795. PubMed ID: 36066378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition.
    Zhao Z; Zhao S; Luo L; Xiang Q; Zhu Z; Wang J; Liu Y; Luo J
    Br J Cancer; 2021 Mar; 124(5):982-994. PubMed ID: 33239676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
    Altschuler J; Stockert JA; Kyprianou N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Cancer, Race, and Health Disparity: What We Know.
    Roach M; Coleman PW; Kittles R
    Cancer J; 2023 Nov-Dec 01; 29(6):328-337. PubMed ID: 37963367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
    Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
    Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs and epithelial-mesenchymal transition in prostate cancer.
    Sekhon K; Bucay N; Majid S; Dahiya R; Saini S
    Oncotarget; 2016 Oct; 7(41):67597-67611. PubMed ID: 27588490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients.
    Parol M; Gzil A; Bodnar M; Grzanka D
    J Transl Med; 2021 Jan; 19(1):28. PubMed ID: 33413466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.
    Chornokur G; Dalton K; Borysova ME; Kumar NB
    Prostate; 2011 Jun; 71(9):985-97. PubMed ID: 21541975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Contributions to Prostate Cancer Disparities in Men of West African Descent.
    Johnson JR; Woods-Burnham L; Hooker SE; Batai K; Kittles RA
    Front Oncol; 2021; 11():770500. PubMed ID: 34820334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015.
    Williams VL; Awasthi S; Fink AK; Pow-Sang JM; Park JY; Gerke T; Yamoah K
    Cancer Med; 2018 May; 7(5):2160-2171. PubMed ID: 29601662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access and Representation: A Narrative Review of the Disparities in Access to Clinical Trials and Precision Oncology in Black men with Prostate Cancer.
    Esdaille AR; Ibilibor C; Holmes A; Palmer NR; Murphy AB
    Urology; 2022 May; 163():90-98. PubMed ID: 34582887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.